Risk factors for febrile neutropenia and effectiveness of primary prophylaxis with pegfilgrastim in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil

Table 3 Comparison of adverse events between the two groups

	Total (n = 92)	Pegfilgrastim (n = 33)	Control (n = 59)	p value
CTCAE ≥ grade 3				< 0.001
Yes	45	4	41
No	47	29	18
CTCAE grade 4				0.018
Yes	9	0	9
No	83	33	50
Neutropenia				< 0.001
Yes	39	3	36
No	53	30	23
Febrile neutropenia				0.001
Yes	20	1	19
No	72	32	40
Hyponatremia				0.643
Yes	4	1	3
No	88	32	56
Anorexia				0.216
Yes	7	1	6
No	85	32	53
Nausea				0.285
Yes	2	0	2
No	90	33	57
G-CSF (filgrastim) use				< 0.001
Yes	31	0	31
No	61	33	28
Next cycle DCF therapy				0.006
Planed administration	72	31	41
Reduced/interruption	20	2	18

ISSN: 1477-7819